Cargando…
Development of a Brazilian anticholinergic activity drug scale
OBJECTIVE: To develop a scale of anticholinergic activity drugs used in Brazil, to be applied in health care and pharmacoepidemiology research. METHODS: We performed a literature review on PubMed/MEDLINE(®) to identify previously published scales of anticholinergic drugs. This scale started with ant...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto Israelita de Ensino e Pesquisa Albert Einstein
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443211/ https://www.ncbi.nlm.nih.gov/pubmed/30942279 http://dx.doi.org/10.31744/einstein_journal/2019AO4435 |
_version_ | 1783407824388227072 |
---|---|
author | Nery, Raiany Thaimeny Reis, Adriano Max Moreira |
author_facet | Nery, Raiany Thaimeny Reis, Adriano Max Moreira |
author_sort | Nery, Raiany Thaimeny |
collection | PubMed |
description | OBJECTIVE: To develop a scale of anticholinergic activity drugs used in Brazil, to be applied in health care and pharmacoepidemiology research. METHODS: We performed a literature review on PubMed/MEDLINE(®) to identify previously published scales of anticholinergic drugs. This scale started with anticholinergic drugs, and those with known anticholinergic activity as per the 4(th) level, chemical-therapeutic subgroup, of the Anatomical Therapeutic Chemical classification. We also included drugs with high anticholinergic activity, as described in a list of potentially inappropriate medications for use in older adults, according to the 2015 American Geriatrics Society Beers Criteria. Drugs listed in at least two anticholinergic scales were added. Then we verified which drugs in the previous steps were marketed in Brazil. We assigned a score of 1, 2 and 3, based on their anticholinergic action. RESULTS: A total of 273 anticholinergic drugs were identified, of which 125 were included in the scale. We identified 45 (36.0%) drugs with a score of 3, 13 (10.4%) with a score of 2, and 67 (53.6%) with a score of 1. Drugs for the nervous and respiratory systems were the most frequent in the scale. Eight drugs were not present in previous scales. CONCLUSION: The methodology used for development of the Brazilian anticholinergic activity scale is simple, systematized, reproducible and easy to update. The scale allows evaluating the impact of anticholinergic burden on health outcomes, and can potentially contribute to pharmacoepidemiology research, leading to more accurate measurements of anticholinergic activity. |
format | Online Article Text |
id | pubmed-6443211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Instituto Israelita de Ensino e Pesquisa Albert Einstein |
record_format | MEDLINE/PubMed |
spelling | pubmed-64432112019-04-05 Development of a Brazilian anticholinergic activity drug scale Nery, Raiany Thaimeny Reis, Adriano Max Moreira Einstein (Sao Paulo) Original Article OBJECTIVE: To develop a scale of anticholinergic activity drugs used in Brazil, to be applied in health care and pharmacoepidemiology research. METHODS: We performed a literature review on PubMed/MEDLINE(®) to identify previously published scales of anticholinergic drugs. This scale started with anticholinergic drugs, and those with known anticholinergic activity as per the 4(th) level, chemical-therapeutic subgroup, of the Anatomical Therapeutic Chemical classification. We also included drugs with high anticholinergic activity, as described in a list of potentially inappropriate medications for use in older adults, according to the 2015 American Geriatrics Society Beers Criteria. Drugs listed in at least two anticholinergic scales were added. Then we verified which drugs in the previous steps were marketed in Brazil. We assigned a score of 1, 2 and 3, based on their anticholinergic action. RESULTS: A total of 273 anticholinergic drugs were identified, of which 125 were included in the scale. We identified 45 (36.0%) drugs with a score of 3, 13 (10.4%) with a score of 2, and 67 (53.6%) with a score of 1. Drugs for the nervous and respiratory systems were the most frequent in the scale. Eight drugs were not present in previous scales. CONCLUSION: The methodology used for development of the Brazilian anticholinergic activity scale is simple, systematized, reproducible and easy to update. The scale allows evaluating the impact of anticholinergic burden on health outcomes, and can potentially contribute to pharmacoepidemiology research, leading to more accurate measurements of anticholinergic activity. Instituto Israelita de Ensino e Pesquisa Albert Einstein 2019-03-18 /pmc/articles/PMC6443211/ /pubmed/30942279 http://dx.doi.org/10.31744/einstein_journal/2019AO4435 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Nery, Raiany Thaimeny Reis, Adriano Max Moreira Development of a Brazilian anticholinergic activity drug scale |
title | Development of a Brazilian anticholinergic activity drug scale |
title_full | Development of a Brazilian anticholinergic activity drug scale |
title_fullStr | Development of a Brazilian anticholinergic activity drug scale |
title_full_unstemmed | Development of a Brazilian anticholinergic activity drug scale |
title_short | Development of a Brazilian anticholinergic activity drug scale |
title_sort | development of a brazilian anticholinergic activity drug scale |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443211/ https://www.ncbi.nlm.nih.gov/pubmed/30942279 http://dx.doi.org/10.31744/einstein_journal/2019AO4435 |
work_keys_str_mv | AT neryraianythaimeny developmentofabraziliananticholinergicactivitydrugscale AT reisadrianomaxmoreira developmentofabraziliananticholinergicactivitydrugscale |